Rabbit antithymocyte globulin induction therapy in adult renal transplantation

Pharmacotherapy

Volumn 26, Issue 12 I, 2006, Pages 1771-1783

  Hardinger, Karen L ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atgam; Basiliximab; Daclizumab; Horse ATG; Induction immunosuppression; Monoclonal induction immunosuppressive agent; Muromonab CD3; OKT3; Rabbit antithymocyte globulin; rATG; Renal transplantation; Thymoglobulin

Indexed keywords

ANTIMETABOLITE; ANTIVIRUS AGENT; B LYMPHOCYTE ANTIGEN; BASILIXIMAB; CALCINEURIN INHIBITOR; CD16 ANTIGEN; CD18 ANTIGEN; CD2 ANTIGEN; CD20 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; CD45 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; CYTOKINE; DACLIZUMAB; DEXAMETHASONE; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHYLPREDNISOLONE; OKT 3; ORTHOCLONE; POLYCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; THYMOCYTE ANTIBODY; UNINDEXED DRUG;

ACUTE GRAFT REJECTION; ALLERGY; ANAPHYLAXIS; ANTIBODY PRODUCTION; ARTHRALGIA; CHILL; CLINICAL PRACTICE; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FEVER; FLU LIKE SYNDROME; HEADACHE; HEART DISEASE; HEMATOLOGIC DISEASE; HERPES SIMPLEX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE SWELLING; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LEUKOPENIA; LUNG EDEMA; LYMPHADENOPATHY; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MYALGIA; NAUSEA; NONHODGKIN LYMPHOMA; PAIN; POSTOPERATIVE COMPLICATION; PRURITUS; RASH; REPEATED DRUG DOSE; REVIEW; SERUM SICKNESS; SHOCK; SIDE EFFECT; SINGLE DRUG DOSE; SYNDROME; THORAX PAIN; TUMOR; URTICARIA;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; CALCINEURIN; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; GLUCOCORTICOIDS; GRAFT REJECTION; HORSES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RABBITS; RECOMBINANT FUSION PROTEINS;

EID: 33845364700     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.12.1771     Document Type: Review

References (44)

1. Ferguson R. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant 1994;8(3 pt 2):328-31.
2. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342(9):605-12.
3. U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients (OPTN/SRTR). OPTN/SRTR 2004 annual report. Available from http://www.optn.org/ar2004/110_can-race_dh.htm?o=1&g=2&c= 1. Accessed August 12, 2005.
4. Pharmacia & Upjohn. Atgam (horse antithymocyte globulin) prescribing information. Kalamazoo, MI; 2003.
5. Genzyme Corporation. Thymoglobulin (rabbit antithymocyte globulin) prescribing information. Cambridge, MA; 2005.
6. IMTIX-SangStat. Thymoglobuline (rabbit antithymocyte globulin) prescribing information. Lyon, France; 2003.
7. Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991;51(3):669-73.
8. Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005;79(11):1507-15.
9. Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003;75(5):657-62.
10. Guttmann RD, Caudrelier P, Alberici G, Touraine JL. Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobuline and immunosuppression. Transplant Proc 1997;29(7A):24S-6.
11. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999;67(7):1011-18.
12. Hardinger KL, Schnitzler MA, Miller B, et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 2004;78(1):136-41.
13. Preville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001;71(3):460-8.
14. Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998;66(1):29-37.
15. Muller TF, Grebe SO, Neumann MC, et al. Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 1997;64(10):1432-7.
16. Wiland AM, Fink JC, Philosophe B, et al. Peripheral administration of rATG for induction therapy in pancreas transplantation. Transplant Proc 2001;33(1-2):1910.
17. Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002;73(3):473-5.
18. + lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 2002;73(9):1514-18.
19. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003;361(9368):1502-10.
20. Stratta RJ, Sundberg AK, Farney AC, Rohr MS, Hartmann EL, Adams PL. Experience with alternate-day Thymoglobulin induction in pancreas transplantation with portal-enteric drainage. Transplant Proc 2005;37(8):3546-8.
21. Shoskes DA, Halloran PF. Delayed graft function in renal transplantation: etiology, management and long-term significance. J Urol 1996;155(6):1831-40.
22. Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003;76(5):798-802.
23. Tanriover B, Chuang P, Fishbach B, et al. Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange. Transplantation 2005;80(2):279-81.
24. Buchler M, Hurault de Ligny B, Madec C, Lebranchu Y. Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy. Clin Transplant 2003;17(6):539-45.
25. Mourad G, Garrigue V, Squifflet JP, et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001;72(6):1050-5.
26. Prin Mathieu C, Renoult E, Kennel De March A, Bene MC, Kessler M, Faure GC. Serum anti-rabbit and anti-horse IgG, IgA, and IgM in kidney transplant recipients. Nephrol Dial Transplant 1997;12(10):2133-9.
27. Regan JF, Campbell K, Smith LV, et al. Sensitization following Thymoglobulin and Atgam rejection therapy as determined with a rapid enzyme-linked immunosorbent assay. Transplant Immunol 1999;7:115-21.
28. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004;4(1):87-93.
29. Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005;80(9):1233-43.
30. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003;76(9):1289-93.
31. Charpentier B, Rostaing L, Berthoux F, et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003;75(6):844-51.
32. Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002;2(1):48-56.
33. Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D. Sequential protocols using basiliximab versus antithymocyte globulins in renal transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004;78(4):584-90.
34. Brennan DC. Thymoglobulin versus Simulect for induction immunosuppression in cadaveric renal transplant recipients: expanded results from a prospective randomized multicenter trial [abstr]. Am J Transplant 2003;3(suppl 5):438.
35. Ayache RA, Lebranchu Y, Lepogamp P, et al. Two-dose Daclizumab induction treatment versus Thymoglobulin in renal transplant patients receiving a mycophenolate mofetil based immunosuppression [abstr]. Am J Transplant 2005;5(suppl 11):187.
36. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000;70(9):1352-9.
37. Lebranchu Y, Aubert P, Bayle F, et al. Could steroids be withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine, and CellCept? One-year results of a double-blind, randomized, multicenter study comparing normal dose versus low dose and withdrawal of steroids. Transplant Proc 2000;32(2):396-7.
38. Kandaswamy R, Melancon JK, Dunn T, et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients: an interim analysis. Am J Transplant 2005;5(6):1529-36.
39. Laftavi MR, Stephan R, Stefanick B, et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 2005;137(3):364-71.
40. Woodle ES. A randomized, prospective, multicenter comparative study evaluating a Thymoglobulin based early corticosteroid cessation regimen in renal transplantation (TRIMS) [abstr]. Am J Transplant 2006;6(suppl 12):673.
41. Woodle ES, Alloway RR, Buell JF, et al. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant 2005;5(11):2740-4.
42. Lebranchu Y, Buchler M, Etienne I. 12-month results of a randomized trial comparing sirolimus versus cyclosporine in 150 transplant patients receiving a cadaveric renal graft [abstr]. Am J Transplant 2005;5(suppl 11):540.
43. Schnitzler MA, Woodward RS, Lowell JA, et al. Economics of the antihymocyte globulins Thymoglobulin and Atgam in the treatment of acute renal transplant rejection. Pharmacoeconomics 2000;17(3):287-93.
44. Murray L, ed. Drug topics red book. Montvale, NJ: Thomson PDR, 2006.